Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
521P XELOX +bev +tislelizumab for first-line treatment of... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
521P XELOX +bev +tislelizumab for first-line treatment of MSS/pMMR RAS-mutated mCRC: A single-arm, phase II study
0
Authors
Kun Ou
4 more
Kun Ou
•
Ma Xingquan
2 more
•
Liqiang Yang
Published
September 1, 2024
Paper
Conversation
0
Reviews
0
Bounties
0
Abstract
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Annals of Oncology
Topics
Physics
Quantum Mechanics
Medicine
Cancer Oncology
Internal Medicine
Show all topics
DOI
10.1016/j.annonc.2024.08.590
